Carlos B. P.
- Country
- Spain
- Department
- Hematology
Research Overview
- Phase 2 Study of Iadademstat in Patients with Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea
- Safety and Efficacy of Ponatinib Plus Asciminib Combination in Chronic Myeloid Leukemia Patients with Resistance to Ponatinib and/or Asciminib
- Phase II Study on Reinduction and Cessation of Ponatinib in Chronic Myelogenous Leukemia Patients in Molecular Response
Data & Insights
Has run more than one trial at 12 of 76 partner sites.
Specializations
Multiple Myeloma
Carlos Bravo-Pérez is involved in clinical research across multiple myeloma, with attention to newly diagnosed, relapsed, refractory, and transplant-ineligible settings. The therapeutic landscape includes proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, and bispecific therapies, reflecting a strong focus on modern myeloma treatment strategies.
- Relapsed/refractory multiple myeloma
- Newly diagnosed multiple myeloma
- Transplant-ineligible disease
- Minimal residual disease
His work also extends to high-risk precursor conditions and post-transplant disease control, supporting therapeutic innovation in plasma cell disorders.
Breast Cancer
His clinical research includes a broad range of breast cancer subtypes, especially HER2-positive, HER2-negative, triple-negative breast cancer, and hormone receptor-positive disease. The studies span early-stage, locally advanced, and metastatic settings, with emphasis on endocrine-based, antibody-based, and antibody-drug conjugate approaches.
- Early breast cancer
- Triple-negative breast cancer
- HER2-positive disease
- Metastatic breast cancer
His interests also include recurrence prevention, residual disease, and biomarker-defined treatment selection in breast oncology.
Hematologic Malignancies and Myeloid Disorders
Carlos Bravo-Pérez is active in research on hematologic malignancies and related myeloid disorders, including acute myeloid leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, myelofibrosis, essential thrombocythaemia, and lymphomas. His portfolio also includes emerging immune-based and targeted therapies for these conditions.
- Myelofibrosis
- Essential thrombocythaemia
- Acute myeloid leukemia
- Follicular lymphoma and diffuse large B-cell lymphoma
This research area also covers post-transplant complications and disease control in advanced hematologic settings.
Autoimmune Cytopenias and Hemostasis
His clinical trial activity includes immune thrombocytopenia, warm autoimmune hemolytic anemia, paroxysmal nocturnal hemoglobinuria, and autoimmune cytopenias, alongside inherited and acquired coagulation-related conditions. The therapeutic focus includes immune modulation, platelet recovery, and prevention of bleeding or thrombotic complications.
- Immune thrombocytopenia
- Warm autoimmune hemolytic anemia
- Paroxysmal nocturnal hemoglobinuria
- Congenital antithrombin deficiency
He is also involved in research addressing thromboembolic disease and supportive care in patients with complex hematologic risk profiles.
Solid Tumors, Transplant-Related Care, and Infectious Disease
His research landscape further includes thyroid cancer, gastric cancer, pancreatic cancer, colorectal cancer, non-small cell lung cancer, and urothelial carcinoma, with additional activity in graft-versus-host disease and HIV-1 infection. These areas reflect interest in targeted oncology, transplant-associated complications, and chronic infectious disease management.
- Thyroid neoplasms
- Gastrointestinal and pancreatic cancers
- Non-small cell lung cancer
- HIV-1 and transplant-related complications
His portfolio also includes studies in neuroendocrine tumors and venous thromboembolism, broadening the therapeutic scope beyond hematology.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.